Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

GROUNDWORK BIOAG AND NOVATERO EXPAND MYCORRHIZAL BIO-PLATFORM FOR BRAZIL

Groundwork BioAg

Groundwork BioAg and its exclusive Brazilian distribution partner, NovaTero BioAg, announced a new product offering for Brazilian farmers this growing season – Rootella® BR ULTRA – which expands the reach to in-furrow and seed treatment application methods in soybean, corn and other cereals. Rootella BR ULTRA is the highest concentrated mycorrhizal inoculant in the market, containing 167,000 viable propagules per gram of Rhizophagus intraradices, with an application rate of as low as 15 grams per hectare. “As farmers manage the unseasonably dry weather, our expanded product portfolio offers additional choices for farmers in Brazil, especially as many switch to Safrinha,” said Bernardo Arnaud, NovaTero Chairman. “Farmers across Brazil continue to benefit from adding Rootella to their farm management practices to protect soil and plant health while extending above and below ground insurance against environmental stresses.” For the past three years, NovaTero has helped Brazilian farmers to naturally increase yield, reduce dependency on phosphorus and improve carbon sequestration in soil by applying the proven Rootella BR mycorrhizae inoculants. “As part of our strategy to expand our mycorrhizal bio-platform, we continue to set the standard for concentration of cost-effective, commercial scale mycorrhizae,” said Dr. Yossi Kofman, Co-Founder and CEO of Groundwork BioAg. “As the impact of climate change continues around the world, we are committed to help increase the productivity of major crops – like those in key breadbaskets such as Brazil. As the ‘queen of biologicals,’ mycorrhiza offers the strongest natural defense against chronic drought while reducing the need for synthetic fertilizers.” After being granted the only definitive commercial registration in Brazil, the companies’ exclusive partnership has accelerated innovation to meet demand of the rapidly growing Brazilian market, where the biologicals market is projected to show a double digit CAGR in the coming years. The Rootella BR portfolio includes two of the most concentrated formulations of mycorrhizae on the market today. About Groundwork BioAg Groundwork BioAg, a global bioagriculture company, leverages the natural power of mycorrhizal fungi to improve the productivity, sustainability and profitability of commercial agriculture and expand regenerative agriculture practices. Groundwork BioAg is the first to use innovative techniques to solve challenges inherent in high-volume mycorrhizal inoculant production. We will not rest until every hectare of arable land is protected by mycorrhizae and every farmer benefits from higher crop yields while preserving our soils. For more information, visit www.groundworkbioag.com. Contact Details AgTech PR for Groundwork BioAg Jennifer Goldston +1 816-260-0040 jennifer@agtechpr.com Company Website https://www.groundworkbioag.com

February 08, 2022 08:30 AM Central Standard Time

How The US is Leading the World to End COVID

YourUpdateTV

After two years of dealing with COVID issues, everyone is sick of arguing about masks and wants the supply chain fixed, the economy to rebound and kids to stay in school. The United States has been the global leader in the fight donating more than a half a billion vaccine doses and hundreds of millions of dollars. More needs to be done, and it’s in the hands of Congress to pass an emergency plan to End COVID Now. YourUpdateTV spoke to Michelle Nunn, President & CEO of CARE USA and Dr. Angela Wakhweya, CARE USA Senior Director, Health Equity and Rights Team to discuss how the US is leading the world to end COVID. A video accompanying this announcement is available at: https://youtu.be/vbbO4zX15Qw An emergency plan being considered by Congress will put billions of dollars into vaccines that could help reduce the risk of new variants developing that could threaten the United States and finally allow us to get back to normal. END COVID NOW is up with new advertisements across the country starting today, Lead The World and Variants are running nationwide on TV and cable as well as digital and streaming platforms. The Campaign to End COVID Now says This pandemic isn’t going away. Instead, it is a chronic disaster for everyone – families, communities, the whole country. The solution is straightforward and staring us in the face – we must achieve global immunity through ensuring everyone in the world has access to vaccines as quickly as possible. If not, we will continue to see variant after variant spread through our neighborhoods, disrupting and threatening our lives and our children’s lives. To learn more, visit EndCovidNow.com About the Campaign to End Covid: The End Covid Now campaign was formed by public health experts, scientists, and other concerned Americans to pressure our nation’s leaders and pharmaceutical companies to ensure future variants don’t shut down America. The plan to end COVID-19 consists of investing more money in vaccine manufacturing, sharing the vaccine formula so other countries can manufacture and distribute them, and working with allied countries to get more people vaccinated so Americans are safe from future variants. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 07, 2022 12:03 PM Eastern Standard Time

Video

G Medical Innovations (NASDAQ: GMVD) to Open One of the Largest COVID-19 Test Processing Labs and Walk-in Testing Facilities in the U.S.

G Medical Innovations Holdings

G Medical Innovations Holdings Ltd. (NASDAQ: GMVD), a telehealth, medical device, and remote patient monitoring company providing clinical-grade solutions for consumers, medical professionals, and healthcare institutions, today announced that it has secured a 26,000 square foot site in Laguna, CA, to open one of the largest COVID-19 test processing laboratories in the United States for its G Medical Labs, Tests and Services division. “The new facility will enable us to process a dramatic increase in samples we have begun receiving via the distribution success of our LiveNow At-Home PCR test kits developed in partnership with McDade Products, LLC. The first million test kits began shipping to retailers nationally last week, and millions more will be on retailers’ shelves in the coming weeks,” said Dr. Yacov Geva, President, and CEO of G Medical Innovations. The Laguna lab will enable the company to process approximately 100,000 samples per day. The site will also offer same-day, walk-in COVID-19 PCR testing for the general public and has the capacity to process samples for other labs and entities that require expedited results. The facility is expected to open by next week. In January, Pittsburgh-based McDade Products, LLC and G Medical Tests and Services partnered to make millions of FDA EUA-approved COVID-19 PCR collection test kits available for retailers in response to a national shortage of COVID-19 test options. The LiveNow COVID-19 PCR Test Collection Kits provide 24 to 48-hour certified lab results and retail for $9.99. Visit https://www.mcdadegrp.com/ to place orders for the LiveNow PCR Collection Kits. G Medical Labs, Tests and Services currently operates storefront testing locations in California. During the next few months, the company expects to expand its network of storefront testing locations in other U.S. regions to be announced at a later date. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial-stage healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. About McDade Group McDade Products is a division of McDade Group, a privately held specialty sales, marketing, and distribution company serving the U.S. retail industry. Founded in 1994, McDade Group is a growing and dynamic sales, marketing, and distribution services company headquartered in Pittsburgh, PA. The company has expanded to provide solutions in distribution, category management, full-service merchandising, and consulting across the U.S. retail industry. Many of the world’s leading CPG manufacturers rely on the ability of McDade Group to build strong industry relationships and deliver services, insights, and expertise for hundreds of their products. Visit: https://www.mcdadegrp.com/ or LinkedIn: https://www.linkedin.com/company/mcdade-group/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses opening one of the largest COVID-19 test processing laboratories in the United States, that the new facility will enable the company to process a dramatic increase in samples, distribution of At-Home PCR test kits, the processing capacity of the Laguna lab, and that it will offer same-day, walk-in COVID-19 PCR testing, the timing of the opening of the facility, and that during the next few months, the company expects to expand its network of storefront testing locations in other U.S. regions to be announced at a later date. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, the registration statement on Form F-1 filed on January 31, 2022 (registration no. 333-262422) and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Investor Relations CONTACT: G Medical Innovations Contact Details G-Medical Innovations Kobi Ben-Efraim, CFO +972 8-958-4777 Kobi@gmedinnovations.com Company Website https://gmedinnovations.com/

February 07, 2022 07:00 AM Eastern Standard Time

New Research Finds the Collaborative Care Model is Associated with Reductions in Racial Disparities in Mental Health Care for Pregnant People

Society for Maternal-Fetal Medicine

The collaborative care model, an evidence-based health intervention that is often used in primary care, has been shown to improve health outcomes for people with depression. It is a team-based approach where a physician collaborates with other professionals, including mental health practitioners, to proactively manage a patient’s mental health. The collaborative care model is not commonly used in obstetrics despite the fact that mental health conditions are one of the leading contributors to poor pregnancy outcomes. In a new study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting™, which is being held virtually, researchers will unveil findings that suggest that implementing the collaborative care model during pregnancy not only is associated with improvements in the screening and treatment of depression in pregnancy, but is also associated with reductions in racial disparities in these important steps in mental health care. Researchers analyzed data from 4,710 pregnant and postpartum people who self-identified as either Black or White. Individuals were divided into two groups (before and after implementation of the collaborative care model) and results were analyzed by race. The primary goal of the research was to evaluate how often pregnant people were screened for depression. When a pregnant person screened positive for depression, the researchers also looked at how often treatment was recommended. In the first group, researchers examined data from August 2015 to September 2016 before the collaborative care model was implemented. In the second group, researchers looked at data from September 2017 to February 2019 after the collaborative care model was implemented. The study found that before the collaborative care model was implemented, there were significant disparities between Black and White pregnant people on screening for depression. After collaborative care was implemented, results showed the disparities between the two groups were eliminated. Similarly, for pregnant people who screened positive, implementation of the collaborative care model was associated with elimination of racial disparities in the recommendation for treatment. “In primary care, the collaborative care model allows mental health care to be seamlessly integrated into physical health care,” says one of the study’s authors Emily S. Miller, MD, MPH, a maternal-fetal medicine subspecialist and assistant professor at Northwestern University in Chicago. “In the field obstetrics, however, this model is not often utilized. What’s exciting about our research is that it demonstrates that we can implement a model — collaborative care — that has been used in primary care for years and apply it to the field of obstetrics to not only improve screening and treatment for depression, but also to promote equity.” The next step, say researchers, is to implement the collaborative care model in obstetrics care across the United States to help improve health outcomes for pregnant people with depression. The abstract has been published in the January 2022 supplement of the American Journal of Obstetrics and Gynecology (AJOG ) and can be accessed at no cost on the AJOG website. To view the presentation of this abstract or other Pregnancy Meeting™ abstracts and events, visit the SMFM website or contact Karen Addis at karen@addispr.com or 301-787-2394. ### Contact Details Karen Addis +1 301-787-2394 KAREN@ADDISPR.COM Company Website https://www.smfm.org/

February 05, 2022 10:00 AM Eastern Standard Time

The Importance of Indoor Air Quality

YourUpdateTV

Aire Serv®, a Neighborly® company, is a global franchise providing installation, maintenance and repair of heating, ventilation, air conditioning and indoor air quality systems. Aire Serv® franchisees provide services to residential and commercial customers from more than 200 locations worldwide. Established in 1992, Aire Serv® is part of Neighborly®, is the world’s largest home services franchisor of 29 brands and nearly 5,000 franchises collectively serving 10 million+ customers in nine countries, focused on repairing, maintaining and enhancing homes and businesses, united under one platform serving 10 million+ customers in nine countries. Neighborly® brands are found at Neighborly.com and through the Neighborly App. For more information about Aire Serv®, visit AireServ.com. The quality of the air we breathe has a direct effect on our health and comfort. You may notice some of the more prominent side effects of indoor air pollution, like an unpleasant odor, but many others go undetected. These include headaches, fatigue, respiratory issues, and other serious, long-term conditions. Recently, Hall of Famer and Super Bowl Champion, Jerome “The Bus” Bettis, teamed up with Aire Serv, a Neighborly company, on a nationwide satellite media tour to discuss the importance of indoor air quality, especially when it comes to how pollution can impact workouts. A video accompanying this announcement is available at: https://youtu.be/moFVmGsuRK0 Jerome was diagnosed with asthma at the age of 14 and as an avid athlete, making sure he wasn’t aggravating that condition was critical to his performance level. As a result, he started learning about different air pollutants and discovered that many are actually found within the home. When you’re constantly breathing in air pollutants, it can take a toll on your breathing over time and especially make it difficult to breathe deeply while exercising. When you don’t get enough oxygen, your energy level decreases, which directly impacts the intensity and performance of your workouts. The cleaner the air you breathe, the better you’re setting up your body for a successful training session. Something as simple as changing the air filters quarterly can have a great impact on indoor air quality. Also, being more mindful of the items in your household will help, such as opting for real plants that will help purify the air indoors, buying beeswax or organic candles, and even swapping out dryer sheets and fabric softeners for more natural alternatives. The experts at Aire Serv recommend making sure you have proper ventilation and filtration throughout the home, as well as air treatments to get rid of any bacteria or viruses. To determine what’s best for your home, call a service professional from Aire Serv to test for you, as this will eliminate a lot of the guesswork. Aire Serv service professionals will go through a discovery stage that discusses issues in the home such as dry throat, allergies, asthma, headaches, and fatigue before analyzing the air quality inside of the home. Once the analysis is complete, the service professionals can recommend additional measures to improve the quality of air in the home, including air and duct cleaning, duct sealing, UVC protection, and ionization. For more information, you can visit AireServ.com, or Neighborly.com to learn more about their other home service brands. About Jerome “The Bus” Bettis: The former Pittsburgh Steelers Running Back is one of the best all-time running backs in the NFL (6th overall in rushing). Jerome Bettis was also the recipient of the Walter Payton Man of the Year Award in 2001. “The Bus” finished his NFL career in January 2006 after 13 seasons, retiring immediately following the Pittsburgh Steelers’ 21-10 win over the Seattle Seahawks in Super Bowl XL in his hometown of Detroit. Diagnosed with asthma at age 14, Bettis is a tireless advocate for asthma education and awareness. Bettis founded and establish “The Bus Stops Here Foundation” in 1996 to help improve the quality of life for disadvantaged and underprivileged children. About Aire Serv ®: Aire Serv®, a Neighborly® company, is a global franchise providing installation, maintenance and repair of heating, ventilation, air conditioning and indoor air quality systems. Aire Serv® franchisees provide services to residential and commercial customers from more than 200 locations worldwide. Established in 1992, Aire Serv® is part of Neighborly®, is the world’s largest home services franchisor of 29 brands and nearly 5,000 franchises collectively serving 10 million+ customers in nine countries, focused on repairing, maintaining and enhancing homes and businesses, united under one platform serving 10 million+ customers in nine countries. Neighborly® brands are found at Neighborly.com and through the Neighborly App. For more information about Aire Serv®, visit AireServ.com. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

February 04, 2022 02:54 PM Eastern Standard Time

Video

New Research Finds that Having a Care Manager During Pregnancy Reduces Likelihood of Delivering a Baby Prematurely for Individuals Most at Risk

Society for Maternal-Fetal Medicine

Research shows that pregnant people on Medicaid are more likely to have worse pregnancy outcomes, including preterm birth, compared to those who have private insurance. When a baby is born too early — or prematurely — it puts the infant at greater risk of health complications and death. In 2011, North Carolina implemented the Pregnancy Medical Home (PMH) program, an initiative designed to improve outcomes for pregnant people on Medicaid by providing them with comprehensive care from a team of professionals. In addition to medical providers, the team includes individuals who can help pregnant people address various social and economic factors that put them at greater risk of having a poor pregnancy outcome. In a new study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting™, which is being held virtually, researchers will unveil findings that suggest that providing intensive pregnancy care management — defined as having more than five face-to-face visits with a care manager during pregnancy — reduces preterm birth rates for both Black and white people. Researchers analyzed data from January 2016 to December 2017. The study included 3,565 pregnant people in North Carolina on Medicaid. Individuals were categorized as either high-risk or low-risk using a screening assessment tool, the Maternal-Infant Impactability Score (MIIS). Those classified as high-risk had at least three of the following risk factors: a prior preterm birth, high blood pressure, smoked, used recreational drugs or alcohol, had a mental health condition, experienced domestic violence, had housing instability, or suffered from food insecurity. High-risk pregnant people were then assigned a care manager who provided a range of support during their pregnancy, including calling the pregnant person to check in, accompanying the individual to medical appointments, and helping to address the social and economic factors that put someone at a greater risk of delivering a baby prematurely. Out of study’s 3,565 pregnant people, the overall preterm birth rate was 18.3 percent. Researchers also looked at how effective the screening tool was for pregnant people who were in the highest risk category. Results revealed that when the screening tool was used and assuming pregnant people received subsequent care management, the preterm birth rates for Black and White people decreased. However, the preterm birth rate for Black people decreased significantly from 24.4 percent to 20.1 percent, while the rate decreased only slightly for White people from 15.6 percent to 15.5. When looking simply at the receipt of intensive care management, findings showed that preterm birth rates decreased for both Black and White people, regardless of their risk stratification. For Black people who received intensive care management during pregnancy, the preterm birth rate was 16.9 percent vs. 26.0 percent for Black people who did not receive intensive care management during pregnancy. For White people who received intensive care management during pregnancy, the preterm birth rate was 12.3 percent vs. 17.8 percent for White people who did not receive intensive care management during pregnancy. “Regardless of your risk factors, what this research shows is that if you have intensive care management while you’re pregnant — someone who’s really there for you throughout your pregnancy — it helps lower your risk of delivering your baby prematurely,” says the study’s lead author Divya Mallampati, MD, MPH, a maternal-fetal medicine fellow at University of North Carolina at Chapel Hill. “The research also reveals that people who are at the highest risk benefit the most from having intensive care management during pregnancy.” The next step, say researchers, is to analyze whether the PMH model helps to improve other health outcomes in pregnancy. The abstract has been published in the January 2022 supplement of the American Journal of Obstetrics and Gynecology (AJOG ) and can be accessed at no cost on the AJOG website. To view the presentation of this abstract or other Pregnancy Meeting™ abstracts and events, visit the SMFM website or contact Karen Addis at karen@addispr.com or 301-787-2394. About the Society for Maternal-Fetal Medicine The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for obstetricians who have additional training in high-risk, complicated pregnancies. SMFM represents more than 5,000 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to reduce disparities and optimize the health of high-risk pregnant people and their families. SMFM and its members are dedicated to optimizing maternal and fetal outcomes and assuring medically appropriate treatment options are available to all patients. For more information, visit SMFM.org and connect with the organization on Facebook and Twitter. For the latest 2022 Annual Meeting news and updates, follow the hashtag #smfm22. EMBARGOED FOR RELEASE: Feb. 3, 2022 2:00 p.m. EST Contact Details Karen Addis +1 301-787-2394 KAREN@ADDISPR.COM Company Website https://www.smfm.org/

February 03, 2022 02:00 PM Eastern Standard Time

New Research Finds Chewing Sugar-Free Gum Reduced Preterm Births

Society for Maternal-Fetal Medicine

Each year, an estimated 15 million babies are born prematurely or preterm (defined as delivery before the 37 th week of pregnancy), and this number is rising, according to the World Health Organization. Preterm babies are at greater risk of experiencing serious health problems. Over the last several decades, multiple studies have shown a link between poor oral health and increased occurrence of preterm birth. Researchers have looked at various ways to improve dental health during pregnancy, including doing a “deep-teeth cleaning,” (also called ‘scaling and planing’) which involves removing plaque and tarter on the teeth and below the gum line. However, despite improving periodontitis, deep teeth cleaning approaches have not proven to be effective in the prevention of preterm birth. But now researchers have discovered an easy and inexpensive way to improve oral health and reduce preterm births. In a new study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting™, which is being held virtually, researchers will unveil findings that suggest that daily use of xylitol chewing gum starting pre- or early pregnancy significantly reduced the number of preterm births. Xylitol is a naturally occurring alcohol found in fruits and vegetables and is commonly used as a sugar substitute in chewing gum. The study, the largest of its kind, was conducted over 10 years and included 10,069 women in the South-Central African country of Malawi, which has the highest number of preterm births in the world. Most Malawians live in rural locations, making it especially difficult to conduct of study of this magnitude. The cluster randomized trial enrolled participants from eight health centers in Malawi and was approved by the Malawi Ministry of Health. Participants enrolled voluntarily and consented to participation before they became pregnant or within 20 weeks of becoming pregnant. All of the eight health centers provided health care messages promoting oral health care and preterm birth prevention and care, while half of the eight centers were randomized to also provide xylitol chewing gum to enrolled research participants. In the four health centers that served as the control group, 5,520 participants received basic perinatal and oral health education, including things they could do to help lower the chance of delivering a baby prematurely. In the other four centers, the 4,549 enrolled participants also received this same health education. In addition, they were given xylitol chewing gum and instructed to chew the gum for 10 minutes once a day, ideally twice a day, throughout pregnancy. Out of the 9,670 participants who were available for contact during the up to six years of follow-up, results showed a significant reduction in preterm birth among those who chewed the xylitol containing gum (12.6 percent vs. 16.5 percent) and fewer low birth weight babies, those weighing 5.5 pounds or less (8.9 percent vs. 12.9 percent). Participants also saw an improvement in their oral health. “Using xylitol chewing gum as an intervention prior to 20 weeks of pregnancy reduced preterm births, and specifically late preterm births between 34 to 37 weeks,” says the study’s lead author Kjersti Aagaard, MD, PhD, a Professor in Maternal-Fetal Medicine and Vice Chair of Obstetrics & Gynecology at Texas Children’s and Baylor College of Medicine in Houston. “When we analyzed by birth weight, instead of estimated gestational age at delivery, we similarly showed a significant improvement in the birth weight with one-third fewer low birth weight babies being born.” Adds Aagaard, “What’s unique about our study is that we used a readily available, inexpensive, and palatable means to reduce the risk of a baby being born too soon or too small. There is some real science behind the choice of xylitol chewing gum to improve oral health, and our novel application to improving birth outcomes is exciting. This has been a labor of love with our colleagues in Malawi, and we were honored to work side-by-side to demonstrate that xylitol chewing gum in early or pre-pregnancy improved oral health by reducing periodontal disease in pregnancy, which was strongly associated with our observed reduction of preterm and low birthweight birth in Malawi. This fits with longstanding evidence linking oral health with preterm births.” The next step, say researchers, is to conduct studies in other parts of the world, including in the U.S., to determine whether this invention will be effective in settings where there may be a lower burden of preterm birth tied to oral health. The abstract has been published in the January 2022 supplement of the American Journal of Obstetrics and Gynecology (AJOG ) and can be accessed at no cost on the AJOG website. To view the presentation of this abstract or other Pregnancy Meeting™ abstracts and events, visit the SMFM website or contact Karen Addis at karen@addispr.com or 301-787-2394. ### About the Society for Maternal-Fetal Medicine The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for obstetricians who have additional training in high-risk, complicated pregnancies. SMFM represents more than 5,000 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to reduce disparities and optimize the health of high-risk pregnant people and their families. SMFM and its members are dedicated to optimizing maternal and fetal outcomes and assuring medically appropriate treatment options are available to all patients. For more information, visit SMFM.org and connect with the organization on Facebook and Twitter. For the latest 2022 Annual Meeting news and updates, follow the hashtag #smfm22. EMBARGOED FOR RELEASE: Feb. 3, 2022 10:15 a.m. EST Contact Details Karen Addis +1 301-787-2394 KAREN@ADDISPR.COM Company Website https://www.smfm.org/

February 03, 2022 10:15 AM Eastern Standard Time

New Research Finds Severity of COVID-19 Does Not Differ According to Trimester

Society for Maternal-Fetal Medicine

Research shows that pregnant people who contract COVID-19 are at increased risk of severe complications, including hospitalization, ventilation, and death, compared to pregnant people without COVID-19. However, little is known about how the timing of COVID-19 infection during pregnancy might impact a pregnant person’s risk of developing severe symptoms. In a new study to be presented today at the Society for Maternal-Fetal Medicine’s (SMFM) annual meeting, The Pregnancy Meeting™, which is being held virtually, researchers will unveil findings that suggest that the severity of COVID-19 does not differ by trimester. “Regardless of what trimester they are in, pregnant people are at risk of developing severe COVID illness,” said one of the study’s authors, Rachel Schell, MD, a maternal-fetal medicine fellow at the University of Texas Southwestern Medical Center in Dallas. Researchers identified a group of pregnant people at a single urban hospital in Dallas, Parkland Hospital, and followed the progression of their COVID-19 symptoms. From March 18, 2020 to May 31, 2021, 1,092 pregnant people were diagnosed with COVID-19. Sixty-seven people (6 percent) were diagnosed in the first trimester, 309 (28 percent) in the second trimester, and 716 (66 percent) in the third trimester. There were no significant demographic differences between the groups. Across all trimesters, 993 out of 1092 people (90.9 percent) were either asymptomatic or had mild COVID-19 symptoms, and 35 out of 345 people (10.1 percent) who were initially asymptomatic developed moderate, severe, or critical symptoms. Among pregnant patients who were initially asymptomatic or had mild symptoms in any trimester, 5 percent developed moderate, severe, or critical illness. “This research is helpful for us in counseling patients who test positive for COVID,” said another one of the study’s authors, Emily Adhikari, MD, a maternal-fetal medicine subspecialist at the University of Texas Southwestern Medical Center and medical director of perinatal infectious diseases at Parkland Hospital. “There is no reason to be hesitant to get vaccinated because you are early in your pregnancy. You’re still at risk of getting really sick from COVID in your first trimester.” Researchers are in the process of expanding their research to look at whether there are significant differences or changes in COVID severity by trimester due to the Delta variant. SMFM, the Centers for Disease Control and Prevention (CDC), and the American College of Obstetricians and Gynecologists recommend all pregnant people get vaccinated against COVID-19, noting that the vaccines are safe and effective. Vaccination rates among pregnant people continue to remain low despite evidence showing vaccines can help to prevent severe illness during pregnancy. The latest figures from the CDC show that fewer than 36 percent of pregnant people are vaccinated; vaccination rates are even lower among pregnant people who are Black and Hispanic. The abstract has been published in the January 2022 supplement of the American Journal of Obstetrics and Gynecology (AJOG ) and can be accessed at no cost on the AJOG website. To view the presentation of this abstract or other Pregnancy Meeting™ abstracts and events, visit the SMFM website or contact Karen Addis at karen@addispr.com or 301-787-2394. ### The Society for Maternal-Fetal Medicine (SMFM), founded in 1977, is the medical professional society for obstetricians who have additional training in high-risk, complicated pregnancies. SMFM represents more than 5,000 members who care for high-risk pregnant people and provides education, promotes research, and engages in advocacy to reduce disparities and optimize the health of high-risk pregnant people and their families. SMFM and its members are dedicated to optimizing maternal and fetal outcomes and assuring medically appropriate treatment options are available to all patients. For more information, visit SMFM.org and connect with the organization on Facebook and Twitter. For the latest 2022 Annual Meeting news and updates, follow the hashtag #smfm22. EMBARGOED FOR RELEASE: Feb. 3, 2022 9:00 a.m. EST Contact Details Karen Addis +1 301-787-2394 KAREN@ADDISPR.COM Company Website https://www.smfm.org/

February 03, 2022 09:00 AM Eastern Standard Time

Reaxys to enhance chemistry patents with patent provenance for greater competitive intelligence insights

Elsevier

Elsevier, a global leader in research publishing and information analytics, is pleased to announce its market leading position in chemistry patent coverage and the extension of its collaboration with LexisNexis® PatentSight®. In March 2021, Elsevier launched its initiative to strengthen the existing patent coverage in Reaxys ®. The content expansion resulted in a 15-fold increase in patent coverage and ensures pharma and chemical companies and their researchers do not miss key competitive intelligence insights. The number of discoverable patents in Reaxys now exceeds 30 million, and the Reaxys-PatentSight collaboration will further enhance content with the patents’ ownership information. These insights will enable companies to better understand competitors’ IP strategies, identify innovative players in a field and confidently assess the commercial viability of their projects. Marco Richter, Global Head of Product, LexisNexis Intellectual Property Solutions, said: “Competition is intense in R&D: With an increasingly diverse landscape of players in the pharmaceutical industry — from niche start-ups to emerging biotech companies, to academic research. To strengthen drug discovery capabilities and shorten development cycle, pharma companies often acquire specialized biotech companies or in-license drug candidates active in preclinical and clinical phases. “Keeping up with the latest information about competitor IP activity and new research is a business-critical challenge. We are pleased to be continuing our collaboration with Elsevier to provide companies with more extensive information on IP history and understand that getting new drugs to market is a resource-intensive process for researchers and know our content can help accelerate this.” The Reaxys updates will enhance competitive intelligence by distinguishing “current patent assignee” and “original patent assignee” to track ownership over time, demonstrating which companies are most prominent in a particular field. Easy-to-use search filters will allow users to sort between inventors and current patent holders. Further enhancements to the patent assignee ontology that unify different common and legal names for corporations will be released in 2022. This allows companies to avoid blind spots and stay on top of emerging competitors when assessing the competitive landscape for a technology. Dr. Ivan Krstic, Head of Chemistry Solutions at Elsevier added: “Reaxys users want to clearly view current and past patent holders. These upgrades are in response to their feedback, and underlines our commitment to addressing user needs and responding in a timely manner with significant enhancements to the content and user experience. Because of this virtuous cycle, Reaxys has become the patent discovery space for chemists in pharma and chemical companies. “This work underpins our vision to make Reaxys the most comprehensive, innovative and authoritative chemistry research information system that supports chemistry workflows and use cases, enabling the digital transformation that organizations need to achieve to help drive better research outcomes.” To find out more about the collaboration and patent coverage in Reaxys, visit the Reaxys website. --- About LexisNexis Legal & Professional LexisNexis® Legal & Professional is a leading global provider of legal, regulatory and business information and analytics that help customers increase productivity, improve decision-making and outcomes, and advance the rule of law around the world. As a digital pioneer, the company was the first to bring legal and business information online with its Lexis ® and Nexis ® services. LexisNexis Legal & Professional, which serves customers in more than 150 countries with 10,600 employees worldwide, is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. About LexisNexis Intellectual Property LexisNexis Intellectual Property brings clarity to innovation for businesses worldwide. We enable innovators to accomplish more by helping them make informed decisions, be more productive, comply with regulations and ultimately achieve a competitive advantage for their business. Our suite of workflow and analytics solutions (LexisNexis ® IP Data Direct, LexisNexis PatentAdvisor ®, LexisNexis PatentOptimizer ®, LexisNexis ® PatentSight ® and LexisNexis TotalPatent One ® ) enables companies to be more efficient and effective at bringing meaningful innovations to our world. We are proud to directly support and serve these innovators in their endeavors to better humankind. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, Reaxys, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support, and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including The Lancet and Cell; our 40,000 eBook titles; and our iconic reference works, such as Gray's Anatomy. With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier and LexisNexis are part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. Contact Details David Tucker Elsevier Communications, UK d.tucker@elsevier.com Company Website https://www.elsevier.com/

February 02, 2022 09:00 AM Eastern Standard Time

1 ... 195 196 197 198 199 ... 249